Literature DB >> 29768103

Efficacy of Recombinase Polymerase Amplification to Diagnose Trypanosoma cruzi Infection in Dogs with Cardiac Alterations from an Endemic Area of Mexico.

Matilde Jimenez-Coello1, Thomas Shelite2, Alejandro Castellanos-Gonzalez2, Omar Saldarriaga2, Rocio Rivero3, Antonio Ortega-Pacheco4, Carlos Acevedo-Arcique4, Karla Amaya-Guardia1, Nisha Garg5, Peter Melby2, Bruno L Travi2.   

Abstract

Chagas disease is a lingering Public Health problem in Latin America with ∼5.7 million people infected with Trypanosoma cruzi. Transmission is still taking place in most countries of the Americas, including the United States. Dogs are frequently infected with T. cruzi and its high infection prevalence is associated with increased risk of Chagas disease in humans. The city of Mérida in the Yucatan peninsula is endemic for Chagas disease and canines are frequently infected with T. cruzi. The objective of this study was to evaluate the performance of a qualitative point of care (POC) molecular test (RPA-LF, recombinase polymerase amplification-lateral flow) developed in our laboratory for identifying infected dogs. We used retrospective samples of dogs that came for consultation because of cardiac alterations and proved to be infected with T. cruzi as determined by enzyme-linked immunosorbent assay (ELISA), Western blot, and quantitative PCR (qPCR). The analytical sensitivity indicated that RPA-LF amplified T. cruzi DNA in samples containing almost equal to one to two parasites per reaction. Serial twofold dilutions of T. cruzi epimastigotes showed that the test had 95% (19/20) repeatability at concentrations of two parasites per reaction. The test showed no cross reactivity with human DNA or other protozoan parasites (Trypanosoma rangeli, Leishmania spp., and Plasmodium spp.). RPA-LF had the capacity to amplify all discrete typing units (DTUs I-VI) of T. cruzi that circulate in domestic or extradomestic environments. The RPA-LF had 93.2% (95% confidence interval 87.2-98.1) sensitivity and excellent agreement with qPCR used as gold standard (Cohen's Kappa test = 0.963). ELISA was positive in 96.6% (85/88) of dogs, which together with the molecular tests confirmed the frequent contact with infected triatomine bugs in the city of Mérida. These preliminary results on the diagnostic efficacy of the RPA-LF deserve further large-scale field testing of this POC test for T. cruzi infection in endemic areas.

Entities:  

Keywords:  Chagas disease; Mexico; Trypanosoma cruzi; diagnosis; dogs; molecular test

Mesh:

Substances:

Year:  2018        PMID: 29768103     DOI: 10.1089/vbz.2017.2258

Source DB:  PubMed          Journal:  Vector Borne Zoonotic Dis        ISSN: 1530-3667            Impact factor:   2.133


  4 in total

1.  Parasitological, serological and molecular diagnosis of acute and chronic Chagas disease: from field to laboratory.

Authors:  Alejandro Gabriel Schijman; Julio Alonso-Padilla; Silvia Andrea Longhi; Albert Picado
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-05-23       Impact factor: 2.747

Review 2.  Cannabis, One Health, and Veterinary Medicine: Cannabinoids' Role in Public Health, Food Safety, and Translational Medicine.

Authors:  Sivan Ritter; Lilach Zadik-Weiss; Osnat Almogi-Hazan; Reuven Or
Journal:  Rambam Maimonides Med J       Date:  2020-01-30

Review 3.  Diagnosis of animal trypanosomoses: proper use of current tools and future prospects.

Authors:  Marc Desquesnes; Alireza Sazmand; Marisa Gonzatti; Alain Boulangé; Géraldine Bossard; Sophie Thévenon; Geoffrey Gimonneau; Philippe Truc; Stéphane Herder; Sophie Ravel; Denis Sereno; Etienne Waleckx; Vincent Jamonneau; Philippe Jacquiet; Sathaporn Jittapalapong; David Berthier; Philippe Solano; Laurent Hébert
Journal:  Parasit Vectors       Date:  2022-06-27       Impact factor: 4.047

4.  The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America.

Authors:  Albert Picado; Israel Cruz; Maël Redard-Jacot; Alejandro G Schijman; Faustino Torrico; Sergio Sosa-Estani; Zachary Katz; Joseph Mathu Ndung'u
Journal:  BMJ Glob Health       Date:  2018-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.